Which has the lower trailing P/E, GSK or REGN?

GSK has the lower trailing P/E: GSK trades at 15.81 and REGN at 19.15. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, GSK or REGN?

Over the past five years, REGN grew revenue faster — GSK at a 1.38% CAGR versus REGN at 4.64%.

Does GSK or REGN pay a bigger dividend?

GSK yields 3.78% and REGN yields 0.47% based on trailing dividends and the latest price.

Is GSK or REGN more profitable?

REGN runs the higher net margin — GSK at 14.52% versus REGN at 27.86%.

How have GSK and REGN total returns compared?

Over the past 10 years, GSK delivered 6.11% and REGN delivered 7.45% annualized total return. Past performance doesn't predict future results.

GSK plc (GSK) vs Regeneron Pharmaceuticals, Inc. (REGN)

A side-by-side comparison of GSK plc and Regeneron Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 13, 2026. Differences are shown without an overall score or investment verdict.

GSK

GSK plc

$100.20B

$50.01HealthcareDelayed quote: Sep 15, 2026, 4:00 PM EDT

REGN

Regeneron Pharmaceuticals, Inc.

$79.75B

$774.11HealthcareDelayed quote: Sep 15, 2026, 4:00 PM EDT

Total return — GSK vs REGN

growth of $100 · dividends reinvested · last 10y

GSK +76.2% (+5.8%/yr)REGN +97.4% (+7.0%/yr)REGN compounded faster over this window

GSK REGN

GSK vs REGN: by the numbers

•GSK is the larger company ($100.20B vs $79.75B market cap).
•GSK trades at the lower trailing earnings multiple (15.81 vs 19.15 P/E), one valuation lens rather than an overall verdict.
•REGN converts more revenue to profit (27.86% vs 14.52% net margin).
•REGN grew revenue faster over the past five years (4.64% vs 1.38% CAGR).
•GSK pays the higher dividend yield (3.78% vs 0.47%).

Metrics side by side

Valuation

Metric	GSK	REGN
P/E ratio	15.81	19.15
Forward P/E	N/A	14.20
P/S ratio	2.26	5.13
P/B ratio	4.31	2.51
EV / EBITDA	8.08	17.62
FCF yield	9.31%	4.42%

Profitability

Metric	GSK	REGN
Gross margin	72.71%	84.86%
Operating margin	20.72%	25.56%
Net margin	14.52%	27.86%
ROE	27.67%	13.65%
ROIC	13.95%	9.19%

Dividends

Metric	GSK	REGN
Dividend yield	3.78%	0.47%
Payout ratio	57.45%	9.15%

Growth (annualized)

Metric	GSK	REGN
Revenue CAGR (5Y)	1.38%	4.64%
EPS CAGR (5Y)	-0.71%	5.70%
FCF CAGR (5Y)	-2.45%	15.77%
Total return CAGR (5Y)	8.21%	3.93%

Frequently asked

Which has the lower trailing P/E, GSK or REGN?: GSK has the lower trailing P/E: GSK trades at 15.81 and REGN at 19.15. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, GSK or REGN?: Over the past five years, REGN grew revenue faster — GSK at a 1.38% CAGR versus REGN at 4.64%.
Does GSK or REGN pay a bigger dividend?: GSK yields 3.78% and REGN yields 0.47% based on trailing dividends and the latest price.
Is GSK or REGN more profitable?: REGN runs the higher net margin — GSK at 14.52% versus REGN at 27.86%.
How have GSK and REGN total returns compared?: Over the past 10 years, GSK delivered 6.11% and REGN delivered 7.45% annualized total return. Past performance doesn't predict future results.

Go deeper

Full GSK analysis Full REGN analysis Interactive comparison tool

Dig into the metrics

GSK P/E ratio Regeneron Pharmaceuticals P/E ratio GSK dividend yield Regeneron Pharmaceuticals dividend yield GSK ROE Regeneron Pharmaceuticals ROE GSK operating margin Regeneron Pharmaceuticals operating margin GSK revenue growth Regeneron Pharmaceuticals revenue growth GSK free cash flow Regeneron Pharmaceuticals free cash flow

GSK & Regeneron Pharmaceuticals appear in these rankings

Highest Dividend Yield Stocks Highest ROE Stocks Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 13, 2026.